Anileridine

Anileridine

Clinical data
AHFS/Drugs.com	Monograph
Routes of administration	Tablets, injection
ATC code	N01AH05 (WHO)
Legal status
Legal status	AU: S8 (Controlled) CA: Schedule I DE: Anlage I (Controlled) US: Schedule II
Pharmacokinetic data
Protein binding	> 95%
Metabolism	Hepatic
Identifiers
IUPAC name Ethyl 1-[2-(4-aminophenyl)ethyl]-4-phenylpiperidine-4-carboxylate
CAS Number	144-14-9 Y
PubChem CID	8944
IUPHAR/BPS	7115
DrugBank	DB00913 Y
ChemSpider	8600 Y
UNII	71Q1A3O279
KEGG	D02941 Y
ChEBI	CHEBI:61203 Y
ChEMBL	CHEMBL1201347 N
Chemical and physical data
Formula	C22H28N2O2
Molar mass	352.47 g/mol
3D model (Jmol)	Interactive image
Melting point	83 °C (181 °F)
SMILES O=C(OCC)C3(c1ccccc1)CCN(CCc2ccc(N)cc2)CC3
InChI InChI=1S/C22H28N2O2/c1-2-26-21(25)22(19-6-4-3-5-7-19)13-16-24(17-14-22)15-12-18-8-10-20(23)11-9-18/h3-11H,2,12-17,23H2,1H3 Y Key:LKYQLAWMNBFNJT-UHFFFAOYSA-N Y
NY (what is this?)

Anileridine (trade name: Leritine) is a synthetic analgesic drug and is a member of the piperidine class of analgesic agents developed by Merck & Co. in the 1950s. It differs from pethidine (meperidine) in that the N-methyl group of meperidine is replaced by an N-aminophenethyl group, which increases its analgesic activity.

Anileridine is no longer manufactured in the US or Canada. Anileridine is in Schedule II of the Controlled Substances Act 1970 of the United States as ACSCN 9020 with a zero aggregate manufacturing quota as of 2014. The free base conversion ratio for salts includes 0.83 for the dihydrochloride and 0.73 for the phosphate It is also under international control per UN treaties.

As tablets or injection.

Anileridine usually takes effect within 15 minutes of either oral or intravenous administration, and lasts 2–3 hours. It is mostly metabolized by the liver.